Toth PP - Search Results

1

Lipid-lowering treatment and low-density lipoprotein cholesterol target achievement in patients with type 2 diabetes and acute coronary syndrome.

Ferrières J, Lautsch D, Bramlage P, Horack M, Baxter CA, Ambegaonkar B, Toth PP, Poh KK, De Ferrari GM, Gitt AK. Ferrières J, et al. Among authors: toth pp. Arch Cardiovasc Dis. 2020 Oct;113(10):617-629. doi: 10.1016/j.acvd.2020.05.013. Epub 2020 Aug 29. Arch Cardiovasc Dis. 2020. PMID: 32873522 Free article.

2

Comparative effects of lipid-lowering therapies.

Davidson MH, Toth PP. Davidson MH, et al. Among authors: toth pp. Prog Cardiovasc Dis. 2004 Sep-Oct;47(2):73-104. doi: 10.1016/j.pcad.2004.04.007. Prog Cardiovasc Dis. 2004. PMID: 15586350 Review.

3

When high is low: raising low levels of high-density lipoprotein cholesterol.

Toth PP. Toth PP. Curr Cardiol Rep. 2008 Nov;10(6):488-96. doi: 10.1007/s11886-008-0077-2. Curr Cardiol Rep. 2008. PMID: 18950560 Review.

4

Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.

Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Toth PP, et al. Cardiovasc Diabetol. 2009 May 18;8:26. doi: 10.1186/1475-2840-8-26. Cardiovasc Diabetol. 2009. PMID: 19450274 Free PMC article.

5

Achieving secondary prevention low-density lipoprotein particle concentration goals using lipoprotein cholesterol-based data.

Mathews SC, Mallidi J, Kulkarni K, Toth PP, Jones SR. Mathews SC, et al. Among authors: toth pp. PLoS One. 2012;7(3):e33692. doi: 10.1371/journal.pone.0033692. Epub 2012 Mar 29. PLoS One. 2012. PMID: 22479428 Free PMC article.

6

Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups.

Konerman M, Kulkarni K, Toth PP, Jones SR. Konerman M, et al. Among authors: toth pp. J Clin Lipidol. 2012 Jul-Aug;6(4):368-73. doi: 10.1016/j.jacl.2012.01.004. Epub 2012 Jan 21. J Clin Lipidol. 2012. PMID: 22836074

7

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.

Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ. Toth PP, et al. Cardiovasc Diabetol. 2012 Sep 14;11:109. doi: 10.1186/1475-2840-11-109. Cardiovasc Diabetol. 2012. PMID: 22978715 Free PMC article.

8

Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.

Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Toth PP, et al. Atherosclerosis. 2014 Aug;235(2):585-91. doi: 10.1016/j.atherosclerosis.2014.05.914. Epub 2014 May 22. Atherosclerosis. 2014. PMID: 24956532 Free article.

9

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease.

Toth PP. Toth PP. Vasc Health Risk Manag. 2014 Dec 23;11:9-23. doi: 10.2147/VHRM.S75215. eCollection 2015. Vasc Health Risk Manag. 2014. PMID: 25565858 Free PMC article. Review.

10

Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9.

Quispe R, Al-Hijji M, Swiger KJ, Martin SS, Elshazly MB, Blaha MJ, Joshi PH, Blumenthal RS, Sniderman AD, Toth PP, Jones SR. Quispe R, et al. Among authors: toth pp. J Clin Lipidol. 2015 Jul-Aug;9(4):511-8.e1-5. doi: 10.1016/j.jacl.2015.05.005. Epub 2015 Jun 19. J Clin Lipidol. 2015. PMID: 26228668

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

448 results

Search Page

Filters